Foreign firms have been re-calibrating activities in India over the recent past, with some handing over marketing of mature brands to local partners and others effecting layoffs to fine-tune their go-to-market model. Divestment of non-core products and sites that have been underutilized or hit by altered market dynamics have also formed part of these reviews.
Big Pharma Rescripts India Playbook
Big pharma appears to be resetting operations in India fueling some concerns of waning interest. In Vivo looks at what the realignment means or doesn’t.
